Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
Alzheimer's DiseaseThis is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.
Effects of a NeuroAD System, for the Treatment of Alzheimer Disease
Alzheimer's DiseaseTo evaluate the long-term efficacy of the NeuroAD system
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease...
Amnestic Mild Cognitive ImpairmentAlzheimer's Disease1 moreThis study consists of two parts, Part 1 and Part 2. Part 1 assesses the efficacy and safety of verubecestat (MK-8931) compared with placebo administered for 104 weeks in the treatment of amnestic mild cognitive impairment (aMCI) due to Alzheimer's Disease (AD), also known as prodromal AD. Participants are randomized to receive placebo, or 12 mg or 40 mg verubecestat, once daily. The primary study hypothesis for Part 1 is that ≥1 verubecestat dose is superior to placebo with respect to the change from baseline in the Clinical Dementia Rating scale-Sum of Boxes (CDR-SB) score at 104 weeks. Participants completing Part 1 may choose to participate in Part 2, which is a long term double-blind extension to assess efficacy and safety of verubecestat administered for up to an additional 260 weeks. In Part 2, all participants receive either 12 mg or 40 mg verubecestat, once daily.
Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers
Alzheimer's DiseaseThis is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All subjects will receive rosiglitazone extended-release (RSG XR) 4mg once daily for the first 4 weeks of the study followed by 8mg RSG XR. Subject participation will last until one of 5 conditions applies. After a 52-week open-label treatment phase, subjects will attend a final Follow-Up Visit 6 weeks after the end of treatment. The primary objective of this study is to evaluate the long-term safety and tolerability of RSG XR in subjects with mild-to-moderate AD who have completed AVA105640. The secondary objective of this study is to explore further the long-term efficacy of RSG XR in terms of cognitive function and overall clinical response as a function of apolipoprotein E (APOE) e4 allele status
Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
Alzheimer DiseaseThe aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate Alzheimer's disease.
The Clinical Study of Pitavastatin Treatment for Group of Mild to Moderate Alzheimer's Disease
Alzheimer DiseaseHypercholesterolemiaSome studies suggest that statin medications may be effective against Alzheimer's disease. However, this has not been proven. The purpose of this study is to evaluate the efficacy of pitavastatin in patients with mild to moderate Alzheimer's disease and hypercholesterolemia.
A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease...
Alzheimer's DiseaseThe purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
Alzheimer's DiseaseThe primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
Alzheimer DiseaseDementiaThis is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon...
Alzheimer's DiseaseThe purpose of this study is to evaluate the long-term safety and tolerability of Dimebon in patients with Alzheimer's disease.